Figure 6.

Acquired NE phenotype correlates with chemoresistance in LNCaP cells. (A) LNCaP, LNCaP-NE like, and LNCaP-AI derivatives were examined for differences in cell growth. (B) Viability assay of LNCaP (white bars), LNCaP-NE-like (gray bars), and LNCaP-AI (black bars) cells at 96 hours after treatment with docetaxel, paclitaxel, camptothecin, or phorbol ester (TPA) relative to untreated cells. (C) Verification of efficient PCDH-PC knockdown by qRT-PCR in LNCaP-NE-like cells pretreated 24 hours with either Accell Non-Targeting or PCDH11Y siRNAs and then maintained in the presence or absence of docetaxel for 48 hours. (D) Cell viability as assessed by WST-1 assay using siRNAs treated with LNCaP-NE-like cells alone or subsequently treated with docetaxel for 8 days. (E) As in C except using PC3 cells and 96-hour docetaxel treatment. (F) As in D except using LNCaP-AI cells. Bars represent means ± SEM of quintuplets from one experiment representative of three independent experiments.